MAIA Biotechnology Files 8-K

Ticker: MAIA · Form: 8-K · Filed: Mar 21, 2025 · CIK: 1878313

Sentiment: neutral

Topics: sec-filing, corporate-update

TL;DR

MAIA Bio filed an 8-K on 3/21/25. Standard corporate update.

AI Summary

MAIA Biotechnology, Inc. filed an 8-K on March 21, 2025, reporting other events and financial statements. The filing details the company's incorporation in Delaware and its principal executive offices located at 444 West Lake Street, Suite 1700, Chicago, IL 60606. The report was filed under the Securities Exchange Act of 1934.

Why It Matters

This filing provides an official update on MAIA Biotechnology's corporate and financial reporting status with the SEC.

Risk Assessment

Risk Level: low — This is a routine corporate filing and does not appear to contain significant new business developments or financial risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of March 21, 2025.

When was MAIA Biotechnology, Inc. incorporated?

MAIA Biotechnology, Inc. was incorporated in Delaware.

What is the address of MAIA Biotechnology's principal executive offices?

The principal executive offices of MAIA Biotechnology, Inc. are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.

Under which SEC Act is this report filed?

This report is filed under Section 13 or 15(d) of The Securities Exchange Act of 1934.

What is the registrant's telephone number?

The registrant's telephone number, including area code, is (312) 416-8592.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 21, 2025 regarding MAIA Biotechnology, Inc. (MAIA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing